Skip to main content
. Author manuscript; available in PMC: 2018 Jan 11.
Published in final edited form as: Leuk Res. 2015 Jun 28;39(10):1034–1040. doi: 10.1016/j.leukres.2015.06.012

Fig. 1.

Fig. 1

Comparison of outcome of AML patients with prior cytopenia compared to AML patients without prior cytopenia. (A) Overall survival (OS) of AML-cytopenic patients (n = 29) is shorter than that of AML-non-cytopenic patients (n = 111) (p < 0.0001). (B) Disease-specific survival (DSS) of AML-cytopenic patients is significantly shorter that of AML-non-cytopenic patients (p < 0.0001). (C) Among patients not receiving induction chemotherapy, OS of AML-cytopenic patients (n = 13) is significantly shorter than that of AML-non-cytopenic patients (n = 29) (p = 0.0003). (D) Among patients treated with induction chemotherapy (with or without subsequent stem cell transplant), OS of AML-cytopenic patients (n = 16) is significantly shorter than that of AML-non-cytopenic patients (n = 82) (p = 0.004). (E) Among patients with UKMRC adverse-risk karyotype, there is no significant difference in OS between AML-cytopenic patients (n = 11) and AML-non-cytopenic patients (n = 22) (p = 0.57). (F) Among patients with UKRMC intermediate-risk karyotype, OS of AML-cytopenic patients (n = 18) is significantly shorter than that of AML-non-cytopenic patients (n = 69) (p < 0.0001).